Although other variables may contribute to these observations, both cell lines differ in their BRAF status (LoVo cells express wild-type BRAF, while HT-29 express mutated BRAF), suggesting that CNTD2 favours CRC cell proliferation in the short-term, but it may lead to different outcomes in the long-term based on BRAF status. The gene discussed is BRAF; the disease is colorectal carcinoma.